DISCOVER

Vascepa

EXPERIENCED

in lipid science

INVESTOR

relations

Vascepa

LIPID SCIENCE

investor relations

welcome


therapeutics to improve cardiovascular health

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl) is Amarin's first FDA approved product and is available in the United States by prescription. For more information about Vascepa visit www.vascepa.com.

recent news


4 Jan 2018

Amarin Provides Preliminary 2017 Results and Provides 2018 Outlook MORE

19 Dec 2017

Amarin Announces REDUCE-IT Cardiovascular Outcomes Study Final Patient Visits to Commence in March 2018 MORE

Stock Information

Symbol:
AMRN (NASDAQ)
Quote:
4.1
Change:
-0.01
Date:
17 Jan 2018 9:41 EST
(20 minute delayed share price)
Investor
Relations
Executive
Team
Career
Opportunities
Contact
Amarin

Amarin
Corporation

therapeutics to improve
cardiovascular health.

Join Our Mailing List

You may automatically receive Amarin Corporation plc financial information by email.


Click To Subscribe